# dCas9 (Catalytically Dead Cas9): Transcriptional Activation/Repression (CRISPRa/CRISPRi) and Epigenome Editing


## Key Takeaways

- dCas9 is a catalytically inactive variant of the *Streptococcus pyogenes* Cas9 endonuclease, engineered via D10A and H840A mutations, retaining sequence-specific DNA binding without inducing double-strand breaks. This allows for targeted transcriptional activation (CRISPRa) or repression (CRISPRi) by fusing dCas9 to effector domains like VP64 or KRAB, respectively.
- Beyond transcriptional control, dCas9 serves as a versatile scaffold for epigenome editing, enabling targeted deposition or removal of epigenetic marks such as histone acetylation (e.g., dCas9-p300 for H3K27ac) and DNA methylation (e.g., dCas9-DNMT3A for CpG methylation).
- The modular nature of dCas9 allows fusion with deaminases (e.g., APOBEC1, TadA) to achieve precise base editing (C-to-T or A-to-G conversions) without DSBs, offering a safer alternative for genetic correction compared to traditional gene editing.
- Delivery of dCas9 systems into eukaryotic cells, particularly for therapeutic applications, commonly utilizes adeno-associated virus (AAV) or lentiviral vectors, with considerations for packaging capacity and potential immunogenicity due to the bacterial origin of Cas9.
- Off-target effects, a critical concern for dCas9 applications, can be mitigated through the use of high-fidelity dCas9 variants (e.g., SpCas9-HF1), truncated guide RNAs, or inducible expression systems, ensuring greater specificity and safety in genomic manipulation.

---

## Executive Summary & Key Metadata

dCas9 (catalytically dead Cas9) is an engineered variant of the *Streptococcus pyogenes* Cas9 (SpCas9) endonuclease that retains sequence-specific DNA binding capacity while eliminating all endonucleolytic cleavage activity. This is achieved through two point mutations in the RuvC and HNH nuclease domains: D10A (aspartate-to-alanine at position 10) and H840A (histidine-to-alanine at position 840). The resulting protein functions as a programmable DNA-binding scaffold that can be fused to transcriptional modulators, epigenetic editors, or fluorescent reporters, enabling targeted interrogation and manipulation of the genome without introducing double-strand breaks (DSBs). This manual provides a comprehensive technical reference for dCas9, covering its genomic context, structural biology, molecular mechanisms, clinical applications, and bioinformatic resources.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | dCas9 (engineered variant of *cas9* gene from *S. pyogenes*) |
| **UniProt Accession** | Q99ZW2 (SpCas9 wild-type; dCas9 is a mutant derivative) |
| **Representative PDB ID** | 4ZT0 (SpCas9-sgRNA-DNA ternary complex) |
| **Chromosomal Locus** | Not applicable (bacterial origin; expressed from plasmid or viral vectors in eukaryotic cells) |
| **Primary Molecular Function** | Sequence-specific DNA binding; transcriptional regulation (activation/repression); epigenome editing; base editing (when fused to deaminases) |
| **Disease & Pathology Associations** | Not a human gene; used in therapeutic contexts for genetic disorders, cancer, infectious diseases, and regenerative medicine |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Origin and Genomic Context

The *cas9* gene is encoded within the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) locus of *Streptococcus pyogenes* (strain SF370). The CRISPR locus is organized as an array of repeat-spacer elements flanked by *cas* genes (Cas1, Cas2, Cas9, Csn2). The *cas9* gene spans approximately 4.1 kilobases (kb) and encodes a 1,368-amino-acid protein. In its native bacterial context, Cas9 functions as an RNA-guided endonuclease that cleaves foreign DNA (e.g., bacteriophage genomes) as part of the adaptive immune system [<a href="#ref-1">1</a>].

### 1.2 Codon Optimization and Expression in Eukaryotes

For use in mammalian cells, the *cas9* coding sequence is codon-optimized to match human codon usage frequencies. This optimization eliminates cryptic splice sites, premature polyadenylation signals, and other cis-acting elements that would otherwise reduce expression in eukaryotic hosts. The codon-optimized dCas9 is typically expressed from a CMV (cytomegalovirus) or CAG (chicken β-actin) promoter, often with a nuclear localization signal (NLS) at the N- and/or C-terminus to ensure nuclear import [<a href="#ref-2">2</a>].

### 1.3 Isoforms and Variants

While dCas9 itself is a single engineered protein, multiple functional isoforms exist based on fusion partners:

- **dCas9-VP64**: Fused to the VP64 transcriptional activation domain (four tandem copies of VP16), used for CRISPR activation (CRISPRa).
- **dCas9-KRAB**: Fused to the Krüppel-associated box (KRAB) domain, used for CRISPR interference (CRISPRi).
- **dCas9-p300**: Fused to the catalytic core of the acetyltransferase p300, enabling targeted histone acetylation (H3K27ac).
- **dCas9-TET1/CD**: Fused to the catalytic domain of TET1, enabling targeted DNA demethylation (5mC to 5hmC conversion).
- **dCas9-DNMT3A**: Fused to DNA methyltransferase 3A, enabling targeted DNA methylation (CpG methylation).
- **dCas9-APOBEC**: Fused to cytidine deaminases (e.g., APOBEC1) for base editing (C-to-T conversions) without DSBs.

These fusion proteins are not naturally occurring isoforms but are engineered constructs that expand the functional repertoire of dCas9 [<a href="#ref-3">3</a>].

### 1.4 Promoter Architecture and Regulatory Elements

In the bacterial context, the *cas9* gene is transcribed from a constitutive promoter regulated by the global transcriptional repressor Hfq and the CRISPR-associated protein Csn2. In eukaryotic expression systems, the promoter choice dictates expression levels and tissue specificity. For example, the EF1α promoter provides stable expression across cell types, while the U6 promoter is used for sgRNA expression. The sgRNA is transcribed as a short RNA molecule (~100 nucleotides) containing a 20-nucleotide spacer sequence complementary to the target DNA, followed by a scaffold sequence that binds to Cas9 [<a href="#ref-4">4</a>].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold

The SpCas9 protein is a large, multi-domain enzyme with a bilobed architecture. The two lobes are the **recognition (REC) lobe** and the **nuclease (NUC) lobe**, connected by a flexible arginine-rich bridge helix. The REC lobe is responsible for sgRNA binding and conformational changes upon target recognition, while the NUC lobe contains the two nuclease domains (RuvC and HNH) and the PAM-interacting (PI) domain [<a href="#ref-5">5</a>].

### 2.2 Domain Boundaries and Functional Roles

| **Domain** | **Residues (SpCas9)** | **Function** |
|---|---|---|
| **N-terminal RuvC-like domain** | 1–59, 718–769, 906–918 | Catalytic residues D10 and E762; D10A mutation inactivates this domain |
| **Bridge helix** | 60–93 | Arginine-rich; mediates conformational changes upon sgRNA binding |
| **REC I domain** | 94–179 | Recognizes the sgRNA:DNA heteroduplex; stabilizes the R-loop |
| **REC II domain** | 180–308 | Structural support; interacts with REC I |
| **REC III domain** | 309–713 | Contains the HNH nuclease domain; H840A mutation inactivates this domain |
| **HNH nuclease domain** | 775–908 | Catalytic residues H840 and N863; cleaves the target DNA strand |
| **RuvC II domain** | 910–1099 | Structural role; interacts with the non-target DNA strand |
| **PI domain** | 1099–1368 | Recognizes the protospacer adjacent motif (PAM); required for DNA unwinding |

### 2.3 Catalytic Site Mutations (D10A and H840A)

The D10A mutation in the RuvC domain abolishes cleavage of the non-target DNA strand, while the H840A mutation in the HNH domain abolishes cleavage of the target strand. Together, these mutations convert Cas9 into a "dead" nuclease that retains high-affinity, sequence-specific DNA binding. Structural studies using PDB 4ZT0 (SpCas9-sgRNA-DNA ternary complex) reveal that the D10A and H840A mutations do not perturb the overall fold or the sgRNA:DNA interaction interface, confirming that dCas9 maintains the same binding specificity as wild-type Cas9 [<a href="#ref-5">5</a>].

### 2.4 PAM Recognition and DNA Unwinding

The PI domain recognizes the PAM sequence 5'-NGG-3' (where N is any nucleotide). Upon PAM binding, the PI domain induces local DNA unwinding, allowing the sgRNA to base-pair with the complementary strand. The REC lobe undergoes a large conformational rearrangement, transitioning from an open (inactive) to a closed (active) state. In dCas9, this conformational change still occurs, enabling stable R-loop formation and sequence-specific binding [<a href="#ref-6">6</a>].

### 2.5 Structural Dynamics and Allostery

Single-molecule FRET studies have shown that dCas9 undergoes a two-step binding mechanism: (1) rapid, non-specific DNA scanning via three-dimensional diffusion, and (2) PAM-dependent recognition followed by R-loop propagation. The HNH domain remains in a catalytically inactive conformation in dCas9, but the REC lobe still undergoes the "closing" motion, which is essential for high-affinity binding. This allosteric coupling between PAM recognition and R-loop formation is critical for the specificity of dCas9-based tools [<a href="#ref-7">7</a>].

### 2.6 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load dCas9 (PDB: 4ZT0)](/tools/protein-structure-viewer?source=direct&pdbId=4ZT0)

The visualizer allows users to explore the atomic coordinates of the SpCas9-sgRNA-DNA complex, highlighting the D10A and H840A mutation sites, the PAM-interacting domain, and the sgRNA scaffold. Users can toggle between cartoon, surface, and electrostatic representations to examine the electrostatic potential of the DNA-binding groove.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 CRISPR Interference (CRISPRi)

CRISPRi leverages dCas9 fused to the KRAB domain, which recruits the KAP1 (KRAB-associated protein 1) co-repressor complex. KAP1 recruits the SETDB1 histone methyltransferase and the NuRD (nucleosome remodeling and deacetylase) complex, leading to H3K9me3 deposition and chromatin compaction. This results in transcriptional repression of the target gene. CRISPRi is highly specific, with minimal off-target effects when the sgRNA is designed with high specificity [<a href="#ref-8">8</a>].

### 3.2 CRISPR Activation (CRISPRa)

CRISPRa uses dCas9 fused to transcriptional activators such as VP64, p65, and Rta (VPR). These domains recruit the Mediator complex and general transcription factors (e.g., TFIID) to the target promoter, enhancing [RNA polymerase](/knowledge/bioinformatics/rna-polymerase-structure-transcription-mechanisms) II (Pol II) recruitment and transcriptional initiation. Synergistic activation can be achieved by tethering multiple activator domains to the same dCas9 molecule or by using multiple sgRNAs targeting the same promoter [<a href="#ref-9">9</a>].

### 3.3 Epigenome Editing

dCas9 can be fused to epigenetic enzymes to write or erase specific histone modifications and DNA methylation marks:

- **Histone acetylation**: dCas9-p300 catalyzes H3K27ac, which is associated with active enhancers and promoters. This modification recruits bromodomain-containing proteins (e.g., BRD4) and promotes chromatin decondensation.
- **Histone methylation**: dCas9-LSD1 (lysine-specific demethylase 1) erases H3K4me1/2, while dCas9-EZH2 (enhancer of zeste homolog 2) deposits H3K27me3, a repressive mark.
- **DNA methylation**: dCas9-DNMT3A methylates CpG dinucleotides in promoter regions, leading to transcriptional silencing. Conversely, dCas9-TET1 catalyzes the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), promoting gene reactivation [<a href="#ref-10">10</a>].

### 3.4 Base Editing

dCas9 fused to cytidine deaminases (e.g., APOBEC1) or adenine deaminases (e.g., TadA) enables single-nucleotide editing without DSBs. Cytidine base editors (CBEs) convert C-to-T, while adenine base editors (ABEs) convert A-to-G. These tools rely on the DNA-binding specificity of dCas9 to position the deaminase at the target site, with the nicks (if any) introduced by a nickase variant (nCas9) to bias repair toward the desired outcome [<a href="#ref-11">11</a>].

### 3.5 Protein-Protein Interaction Networks

dCas9 interacts with a wide range of proteins depending on its fusion partner. Key interactions include:

- **KRAB-KAP1**: Mediates heterochromatin formation and transcriptional silencing.
- **VP64-Mediator**: Enhances Pol II recruitment and transcriptional activation.
- **p300-CBP**: Catalyzes histone acetylation and chromatin remodeling.
- **DNMT3A-DNMT3L**: Mediates de novo DNA methylation.
- **TET1-TDG**: Facilitates DNA demethylation via base excision repair.

These interactions are context-dependent and can be modulated by post-translational modifications (e.g., phosphorylation of KAP1 by ATM) [<a href="#ref-12">12</a>].

### 3.6 Regulatory Feedback Loops

dCas9-based systems can be engineered to create synthetic feedback loops. For example, a dCas9-VP64 construct targeting a positive autoregulatory gene can create a bistable switch, while dCas9-KRAB targeting a repressor can create a negative feedback loop. These synthetic circuits are used in gene therapy and synthetic biology applications to achieve precise temporal control of gene expression [<a href="#ref-13">13</a>].

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutations in the dCas9 Coding Sequence

While dCas9 is not a human gene, mutations in the *cas9* coding sequence can affect its function. Key mutations include:

- **D10A and H840A**: These are the canonical inactivating mutations that define dCas9. They abolish nuclease activity but preserve DNA binding.
- **D1135E, R1335Q, T1337R**: These mutations alter PAM specificity (e.g., SpCas9-VQR recognizes 5'-NGAG-3' instead of 5'-NGG-3').
- **R780A and K810A**: These mutations reduce off-target binding by destabilizing non-specific DNA interactions.
- **N497A, R661A, Q695A, Q926A**: These mutations (SpCas9-HF1) reduce off-target cleavage by disrupting non-specific contacts with the DNA backbone.

### 4.2 ClinVar Classifications and Pathogenicity

Since dCas9 is an engineered protein, ClinVar does not list pathogenic variants for it. However, in therapeutic contexts, unintended mutations in the dCas9 coding sequence can arise during vector production or genomic integration. These mutations may reduce binding specificity, increase off-target effects, or impair fusion partner activity. Quality control measures, including Sanger sequencing and next-generation sequencing of the dCas9 transgene, are essential to ensure therapeutic safety [<a href="#ref-14">14</a>].

### 4.3 Disease Phenotypes and Therapeutic Applications

dCas9 is used to model and treat a variety of diseases:

- **Genetic disorders**: dCas9-based activation of fetal hemoglobin (HBG1/2) is being explored for β-thalassemia and sickle cell disease.
- **Cancer**: dCas9-KRAB targeting oncogenes (e.g., MYC, BCL2) can suppress tumor growth; dCas9-VP64 targeting tumor suppressors (e.g., TP53) can restore their expression.
- **Infectious diseases**: dCas9 can be programmed to target viral genomes (e.g., HIV-1 LTR) for transcriptional repression or activation of latent proviruses.
- **Neurodegenerative diseases**: dCas9-mediated epigenetic editing of genes such as SNCA (α-synuclein) or APP (amyloid precursor protein) is being investigated for Parkinson's and Alzheimer's diseases [<a href="#ref-15">15</a>].

### 4.4 Off-Target Effects and Mitigation Strategies

Off-target binding of dCas9 can lead to unintended transcriptional modulation. Mitigation strategies include:

- **High-fidelity variants**: SpCas9-HF1 and eSpCas9(1.1) reduce off-target binding.
- **Truncated sgRNAs**: Shortening the sgRNA to 17–18 nucleotides reduces off-target effects.
- **Inducible dCas9**: Fusing dCas9 to a destabilizing domain (e.g., ddCas9) allows temporal control of protein levels.
- **Split-dCas9**: Splitting dCas9 into two fragments that reconstitute only in the presence of a small molecule (e.g., rapamycin) reduces constitutive activity [<a href="#ref-16">16</a>].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Anti-CRISPR Proteins

Bacteriophages encode anti-CRISPR (Acr) proteins that inhibit Cas9 activity. AcrIIA4 and AcrIIC3 are potent inhibitors of SpCas9, binding to the PAM-interacting domain and preventing DNA binding. These proteins can be used to regulate dCas9 activity in therapeutic applications, providing a "safety switch" to limit off-target effects. Structural studies have shown that AcrIIA4 mimics the PAM-containing DNA strand, occupying the PAM-binding pocket and sterically blocking DNA recognition [<a href="#ref-17">17</a>].

### 5.2 Viral Vectors for dCas9 Delivery

dCas9 is commonly delivered via adeno-associated virus (AAV) vectors, lentiviral vectors, or lipid nanoparticles (LNPs). AAV vectors have a packaging limit of ~4.7 kb, which poses a challenge for the 4.1-kb dCas9 coding sequence. To overcome this, split-dCas9 systems or smaller Cas9 orthologs (e.g., SaCas9, CjCas9) are used. Lentiviral vectors can package larger transgenes but carry a risk of insertional mutagenesis. LNPs offer a non-viral alternative with reduced immunogenicity [<a href="#ref-18">18</a>].

### 5.3 Immune Evasion and Immunogenicity

The bacterial origin of dCas9 can elicit an immune response in humans. Pre-existing antibodies against SpCas9 are present in a significant fraction of the population due to prior exposure to *S. pyogenes*. This immunogenicity can reduce the efficacy of dCas9-based therapies and cause adverse reactions. Strategies to mitigate immunogenicity include:

- **Using Cas9 orthologs from less common bacteria** (e.g., *Staphylococcus aureus* Cas9).
- **Chemical modification of dCas9** (e.g., PEGylation) to reduce immune recognition.
- **Transient immunosuppression** during therapy [<a href="#ref-19">19</a>].

---

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 Small-Molecule Inhibitors of dCas9

Small molecules that inhibit dCas9 activity are valuable tools for controlling the timing and duration of CRISPR-based interventions. Known inhibitors include:

- **BRD0539**: A small molecule that disrupts the Cas9-sgRNA interaction, reducing DNA binding.
- **AcrIIA4-derived peptides**: Synthetic peptides that mimic the anti-CRISPR protein and block PAM recognition.
- **Rapamycin**: Used in split-dCas9 systems to induce reconstitution; withdrawal of rapamycin inactivates dCas9.

### 6.2 FDA-Approved Drugs and Investigational Therapies

As of 2026, no dCas9-based therapy has received FDA approval, but several are in clinical trials:

- **CTX001 (CRISPR Therapeutics/Vertex)**: Uses Cas9 to disrupt BCL11A in hematopoietic stem cells for β-thalassemia and sickle cell disease. Although this uses wild-type Cas9, dCas9-based approaches are being developed for safer, non-cleaving alternatives.
- **EDIT-101 (Editas Medicine)**: Uses Cas9 to correct a mutation in the CEP290 gene for Leber congenital amaurosis. dCas9-based epigenetic editing is a potential next-generation approach.
- **VERVE-101 (Verve Therapeutics)**: Uses base editing (dCas9-deaminase fusion) to inactivate [PCSK9](/knowledge/bioinformatics/genes/medical-genetics/pcsk9-gene-structure-function-pathway) for familial hypercholesterolemia [<a href="#ref-20">20</a>].

### 6.3 Gene Therapy Vectors

dCas9-based gene therapy vectors are designed to deliver both the dCas9 fusion protein and the sgRNA. Key considerations include:

- **Promoter selection**: Tissue-specific promoters (e.g., TBG for liver, SYN1 for neurons) restrict expression to target tissues.
- **sgRNA multiplexing**: Multiple sgRNAs can be expressed from a single polycistronic transcript using tRNA processing or ribozyme cleavage.
- **Dose optimization**: The ratio of dCas9 to sgRNA affects on-target efficiency and off-target effects [<a href="#ref-21">21</a>].

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession** | **Description** |
|---|---|---|
| **NCBI Gene** | 901176 (SpCas9) | Gene entry for *S. pyogenes* Cas9 |
| **Ensembl** | Not applicable (bacterial) | No Ensembl entry for bacterial genes |
| **UniProt** | Q99ZW2 | SpCas9 wild-type protein sequence |
| **RCSB PDB** | 4ZT0 | SpCas9-sgRNA-DNA ternary complex |
| **Gene Ontology (GO)** | GO:0004519 (endonuclease activity), GO:0003677 (DNA binding) | Functional annotations for Cas9 |
| **STRING** | Not applicable | No protein-protein interaction data for bacterial Cas9 |
| **BioGRID** | Not applicable | No interaction data for bacterial Cas9 |
| **Addgene** | Various (e.g., #61420 for dCas9-VP64) | Plasmid repositories for dCas9 constructs |
| **CRISPOR** | Not applicable | sgRNA design tool for dCas9 targets |
| **ClinVar** | Not applicable | No clinical variants for dCas9 |

---

## 8. Mermaid Diagram: dCas9-Mediated Transcriptional Regulation

```mermaid
sequenceDiagram
    participant sgRNA as "sgRNA (20-nt spacer)"
    participant dCas9 as "dCas9 (D10A/H840A)"
    participant PAM as "PAM (NGG)"
    participant DNA as "Target DNA"
    participant KRAB as "KRAB Domain"
    participant KAP1 as "KAP1 Co-repressor"
    participant SETDB1 as "SETDB1 Methyltransferase"
    participant Chromatin as "Chromatin (H3K9me3)"
    sgRNA->>dCas9: Binds to REC lobe
    dCas9->>DNA: Scans for PAM sequence
    DNA->>PAM: PAM recognition by PI domain
    PAM->>dCas9: Induces conformational change
    dCas9->>DNA: R-loop formation (sgRNA:DNA hybrid)
    dCas9->>KRAB: Fusion protein recruits KRAB
    KRAB->>KAP1: Recruits KAP1
    KAP1->>SETDB1: Recruits SETDB1
    SETDB1->>Chromatin: Deposits H3K9me3
    Chromatin-->>DNA: Transcriptional repression
```

---

## 9. Conclusion

dCas9 represents a paradigm shift in genome engineering, transforming a bacterial endonuclease into a programmable, non-cleaving DNA-binding platform. Its applications span transcriptional regulation, epigenome editing, base editing, and synthetic biology, with profound implications for basic research and clinical therapy. The structural and mechanistic insights detailed in this manual provide a foundation for understanding dCas9's function and for designing next-generation tools with improved specificity, efficacy, and safety. As the field progresses, dCas9-based technologies are poised to become standard tools in precision medicine, offering unprecedented control over gene expression and epigenetic states.

---

## Related Clinical & Scientific Guides

* [GFP (Green Fluorescent Protein): Beta-Barrel Chromophore Physics, Fluorophore Engineering, and Live-Cell Imaging](/knowledge/bioinformatics/genes/model-organisms/gfp-gene-structure-function-pathway)
* [cdc28 (CDK1): Master Cyclin-Dependent Kinase of Cell Cycle Transitions and Cell Division Control](/knowledge/bioinformatics/genes/model-organisms/cdc28-gene-structure-function-pathway)
* [HoxA9 Homeobox: Homeodomain DNA-Binding Architecture, Body Axis Patterning, and Leukemic Transformation](/knowledge/bioinformatics/genes/model-organisms/hoxa9-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*, 337(6096), 816–821. https://doi.org/10.1126/science.1225829

<a id="ref-2"></a>[2] Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., ... & Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. *Science*, 339(6121), 819–823. https://doi.org/10.1126/science.1231143

<a id="ref-3"></a>[3] Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell*, 152(5), 1173–1183. https://doi.org/10.1016/j.cell.2013.02.022

<a id="ref-4"></a>[4] Hsu, P. D., Lander, E. S., & Zhang, F. (2014). Development and applications of CRISPR-Cas9 for genome engineering. *Cell*, 157(6), 1262–1278. https://doi.org/10.1016/j.cell.2014.05.010

<a id="ref-5"></a>[5] Nishimasu, H., Ran, F. A., Hsu, P. D., Konermann, S., Shehata, S. I., Dohmae, N., ... & Nureki, O. (2014). Crystal structure of Cas9 in complex with guide RNA and target DNA. *Cell*, 156(5), 935–949. https://doi.org/10.1016/j.cell.2014.02.001

<a id="ref-6"></a>[6] Anders, C., Niewoehner, O., Duerst, A., & Jinek, M. (2014). Structural basis of PAM-dependent target DNA recognition by the [Cas9 endonuclease](/knowledge/bioinformatics/genes/microbiology-amr/cas9-gene-structure-function-pathway). *Nature*, 513(7519), 569–573. https://doi.org/10.1038/nature13579

<a id="ref-7"></a>[7] Sternberg, S. H., Redding, S., Jinek, M., Greene, E. C., & Doudna, J. A. (2014). DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. *Nature*, 507(7490), 62–67. https://doi.org/10.1038/nature13011

<a id="ref-8"></a>[8] Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., ... & Qi, L. S. (2013). CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. *Cell*, 154(2), 442–451. https://doi.org/10.1016/j.cell.2013.06.044

<a id="ref-9"></a>[9] Chavez, A., Scheiman, J., Vora, S., Pruitt, B. W., Tuttle, M., P R Iyer, E., ... & Church, G. M. (2015). Highly efficient Cas9-mediated transcriptional programming. *Nature Methods*, 12(4), 326–328. https://doi.org/10.1038/nmeth.3312

<a id="ref-10"></a>[10] Hilton, I. B., D'Ippolito, A. M., Vockley, C. M., Thakore, P. I., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2015). Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. *Nature Biotechnology*, 33(5), 510–517. https://doi.org/10.1038/nbt.3199

<a id="ref-11"></a>[11] Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature*, 533(7603), 420–424. https://doi.org/10.1038/nature17946

<a id="ref-12"></a>[12] Thakore, P. I., D'Ippolito, A. M., Song, L., Safi, A., Shivakumar, N. K., Kabadi, A. M., ... & Gersbach, C. A. (2015). Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. *Nature Methods*, 12(12), 1143–1149. https://doi.org/10.1038/nmeth.3630

<a id="ref-13"></a>[13] Nissim, L., Perli, S. D., Fridkin, A., Perez-Pinera, P., & Lu, T. K. (2014). Multiplexed and programmable regulation of gene networks with an integrated RNA and CRISPR/Cas toolkit in human cells. *Molecular Cell*, 54(4), 698–710. https://doi.org/10.1016/j.molcel.2014.04.022

<a id="ref-14"></a>[14] Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016). High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. *Nature*, 529(7587), 490–495. https://doi.org/10.1038/nature16526

<a id="ref-15"></a>[15] Amrani, N., Gao, X. D., Liu, P., Edraki, A., Mir, A., Ibraheim, R., ... & Sontheimer, E. J. (2018). NmeCas9 is an intrinsically high-fidelity genome-editing platform. *Genome Biology*, 19(1), 214. https://doi.org/10.1186/s13059-018-1591-1

<a id="ref-16"></a>[16] Zetsche, B., Volz, S. E., & Zhang, F. (2015). A split-Cas9 architecture for inducible genome editing and transcription modulation. *Nature Biotechnology*, 33(2), 139–142. https://doi.org/10.1038/nbt.3149

<a id="ref-17"></a>[17] Pawluk, A., Amrani, N., Zhang, Y., Garcia, B., Hidalgo-Reyes, Y., Lee, J., ... & Davidson, A. R. (2016). Naturally occurring off-switches for CRISPR-Cas9. *Cell*, 167(7), 1829–1838. https://doi.org/10.1016/j.cell.2016.11.017

<a id="ref-18"></a>[18] Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., ... & Zhang, F. (2015). In vivo genome editing using Staphylococcus aureus Cas9. *Nature*, 520(7546), 186–191. https://doi.org/10.1038/nature14299

<a id="ref-19"></a>[19] Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., ... & Porteus, M. H. (2019). Identification of preexisting adaptive immunity to Cas9 proteins in humans. *Nature Medicine*, 25(2), 249–254. https://doi.org/10.1038/s41591-018-0326-x

<a id="ref-20"></a>[20] Musunuru, K., Chadwick, A. C., Mizoguchi, T., Garcia, S. P., DeNizio, J. E., Reiss, C. W., ... & Kathiresan, S. (2021). In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. *Nature*, 593(7857), 429–434. https://doi.org/10.1038/s41586-021-03534-y

<a id="ref-21"></a>[21] Banskota, S., Raguram, A., Suh, S., Du, S. W., Davis, J. R., Choi, E. H., ... & Liu, D. R. (2022). Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. *Cell*, 185(2), 250–265. https://doi.org/10.1016/j.cell.2021.12.021